Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
701-720 of 3,900 trials

Chronic Kidney Disease in Children: Finerenone Study

We are studying how well finerenone works and its safety for children with chronic kidney disease and proteinuria. This trial will help us understand its effects when used with standard treatments.

ProteinuriaChronic Kidney Disease6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Chronic Kidney Disease: Finerenone Safety Study

We are studying the long-term safety of finerenone for children and young adults with chronic kidney disease. This trial looks at its effects when used alongside standard treatments like ACE inhibitors or ARBs.

Chronic Kidney DiseaseProteinuria1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Dopaminergic Pathway Changes in Comatose Patients with Traumatic Brain Injury

We are studying how traumatic brain injuries affect dopamine pathways in patients who are in a coma. This research may help us understand recovery patterns and improve future treatments.

Traumatic Brain Injury>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesNeurologyOtolaryngology

Advanced Solid Tumors: DO-2 Drug Study

We are testing a new drug called DO-2 for patients with advanced or hard-to-treat solid tumors. The study aims to understand its safety and how the body processes it.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Refractory Solid Tumors>2 yearsSafety phase (I)Oncology

Advanced Thyroid Cancer: Sacituzumab Govitecan Study

We are testing a new drug for patients with advanced differentiated and anaplastic thyroid neoplasms. The goal is to see if it can effectively control the disease and improve patient outcomes.

Thyroid Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Progressive Pulmonary Fibrosis: Inhaled Treprostinil Study

We are investigating whether inhaled treprostinil can improve lung function in people with progressive pulmonary fibrosis. The study will also assess its safety and impact on overall health.

Progressive Pulmonary Fibrosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPulmonology

Non-Transfusion-Dependent Thalassemia: Luspatercept Treatment

We are studying whether luspatercept can improve brain oxygen levels and blood flow in patients with non-transfusion-dependent thalassemia. The trial also looks at its effects on cognitive function and heart health.

Non-transfusion Dependent Beta-Thalassemia6-12 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHematologyNeurology

Cystic Fibrosis: Long-Term Study of BI 3720931 Gene Therapy

We are monitoring the health of individuals with cystic fibrosis who previously received the BI 3720931 gene therapy. This study aims to assess the long-term safety and effectiveness of the treatment.

Cystic Fibrosis>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPulmonology

Lung Cancer Treatment: MK-2870 vs. Chemotherapy

We are studying a new drug, MK-2870, for patients with advanced lung cancer who have already tried other treatments. The goal is to see if it works better than standard chemotherapy options.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Investigational MedicinesOncology

Prostate Cancer: 177Lu-PSMA Treatment Study

We are studying a new treatment for men with high-risk prostate cancer after initial therapies. The trial aims to see if this treatment helps prevent cancer from coming back and improves quality of life.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

High Cardiovascular Risk: Rosuvastatin vs. Combination Therapy

We are studying whether high-intensity rosuvastatin or a combination of rosuvastatin and ezetimibe can effectively lower cholesterol in patients at high or very high risk for heart disease. The goal is to see if these treatments help achieve specific cholesterol targets.

High Cholesterol≤3 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Dobutamine for Very Preterm Infants with Low Blood Flow

We are studying the lowest effective dose of dobutamine to help improve blood flow in very preterm infants. The trial also looks at how well the treatment works and its safety during the first few days after birth.

Neonates with Haemodynamic Insufficiency>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCardiologyPediatrics

Prostate Cancer Recurrence: PSMA PET/CT vs. Salvage Radiotherapy

We are comparing a personalized treatment approach using PSMA PET/CT imaging with standard salvage radiotherapy for patients whose prostate cancer has returned after surgery. The goal is to see which method better helps manage their condition and improves quality of life.

Recurrent Prostate Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer: MK-2870 with or without Pembrolizumab

We are comparing a new treatment for advanced breast cancer that can't be surgically removed to standard chemotherapy. This study aims to see if the new treatment improves outcomes for patients.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOncology

Non-Small Cell Lung Cancer: V940 and Pembrolizumab Study

We are testing a new treatment combining V940 with pembrolizumab for patients with resected stage II to IIIB non-small cell lung cancer. The study aims to see if this combination improves survival and quality of life compared to a placebo.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Breast Cancer Treatment: Elacestrant with Olaparib

We are studying whether adding elacestrant to the standard treatment olaparib helps women with hormone receptor-positive, HER2-negative breast cancer and gBRCA1/2 mutations. This trial aims to improve progression-free survival and overall treatment outcomes.

Metastatic Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Hysterectomy Pain Relief: Local Anesthetic Study

We are testing whether injecting a local anesthetic before a vaginal hysterectomy helps reduce pain during the procedure. This study is for women undergoing hysterectomy using the vNOTES approach.

Hysterectomy>2 yearsConfirmation phase (III)Gynecology and Obstetrics

Hematologic Malignancies: MK-1026 Treatment Study

We are evaluating a new treatment for patients with blood cancers to see if it is safe and effective in reducing symptoms. This study focuses on various types of hematologic malignancies, including CLL and MCL.

Blood CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Cancer Treatment: Imipramine for Fascin1 Overexpression

We are studying whether Imipramine can change tumor characteristics in patients with cancer that over-express a protein called Fascin1. This research may help us understand its effects on tumor behavior and markers.

Colon and Rectal Cancer3-6 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyOncology

Heart Failure: Stopping Medication After Cardiac Resynchronization Therapy

We are studying the effects of withdrawing medication in patients who have improved heart function after cardiac resynchronization therapy. This trial will help us understand the safety and changes in heart health when treatment is stopped.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine